Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7)

Shunichi Sugawara; Masashi Kondo; Toshihide Yokoyama; Toru Kumagai; Makoto Nishio; Koichi Goto; Kazuhiko Nakagawa; Takashi Seto; Nobuyuki Yamamoto; Kentarou Kudou; Takayuki Asato; Pingkuan Zhang; Yuichiro Ohe

doi:10.1007/s10147-022-02286-7

Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7)

Shunichi Sugawara
, Masashi Kondo
, Toshihide Yokoyama
, Toru Kumagai
, Makoto Nishio
, Koichi Goto
, Kazuhiko Nakagawa
, Takashi Seto
, Nobuyuki Yamamoto
, Kentarou Kudou
, Takayuki Asato
, Pingkuan Zhang
, Yuichiro Ohe

Respiratory Medicine & Clinical Allergy

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In the original publication, under section: Secondary end points, the sentence starting with: “KM estimated...” should read as: KM estimated median DoR was not reached (95% CI 13.9–not reached) in patients who had confirmed responses. The original publication has been corrected.

Original language	English
Pages (from-to)	724-725
Number of pages	2
Journal	International Journal of Clinical Oncology
Volume	28
Issue number	5
DOIs	https://doi.org/10.1007/s10147-022-02286-7
Publication status	Published - 05-2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Surgery
Hematology
Oncology

Access to Document

10.1007/s10147-022-02286-7

Fingerprint

Dive into the research topics of 'Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7)'. Together they form a unique fingerprint.

Cite this

Sugawara, S., Kondo, M., Yokoyama, T., Kumagai, T., Nishio, M., Goto, K., Nakagawa, K., Seto, T., Yamamoto, N., Kudou, K., Asato, T., Zhang, P., & Ohe, Y. (2023). Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7). International Journal of Clinical Oncology, 28(5), 724-725. https://doi.org/10.1007/s10147-022-02286-7

Sugawara, Shunichi ; Kondo, Masashi ; Yokoyama, Toshihide et al. / Correction to : Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7). In: International Journal of Clinical Oncology. 2023 ; Vol. 28, No. 5. pp. 724-725.

@article{f13882e2ad0b4ca99ac95e04cd1448f7,

title = "Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7)",

abstract = "In the original publication, under section: Secondary end points, the sentence starting with: {\textquotedblleft}KM estimated...{\textquotedblright} should read as: KM estimated median DoR was not reached (95\% CI 13.9{\textendash}not reached) in patients who had confirmed responses. The original publication has been corrected.",

author = "Shunichi Sugawara and Masashi Kondo and Toshihide Yokoyama and Toru Kumagai and Makoto Nishio and Koichi Goto and Kazuhiko Nakagawa and Takashi Seto and Nobuyuki Yamamoto and Kentarou Kudou and Takayuki Asato and Pingkuan Zhang and Yuichiro Ohe",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2023.",

year = "2023",

month = may,

doi = "10.1007/s10147-022-02286-7",

language = "English",

volume = "28",

pages = "724--725",

journal = "International Journal of Clinical Oncology",

issn = "1341-9625",

publisher = "Springer",

number = "5",

}

Sugawara, S, Kondo, M, Yokoyama, T, Kumagai, T, Nishio, M, Goto, K, Nakagawa, K, Seto, T, Yamamoto, N, Kudou, K, Asato, T, Zhang, P & Ohe, Y 2023, 'Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7)', International Journal of Clinical Oncology, vol. 28, no. 5, pp. 724-725. https://doi.org/10.1007/s10147-022-02286-7

Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7). / Sugawara, Shunichi; Kondo, Masashi; Yokoyama, Toshihide et al.
In: International Journal of Clinical Oncology, Vol. 28, No. 5, 05.2023, p. 724-725.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Correction to

T2 - Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7)

AU - Sugawara, Shunichi

AU - Kondo, Masashi

AU - Yokoyama, Toshihide

AU - Kumagai, Toru

AU - Nishio, Makoto

AU - Goto, Koichi

AU - Nakagawa, Kazuhiko

AU - Seto, Takashi

AU - Yamamoto, Nobuyuki

AU - Kudou, Kentarou

AU - Asato, Takayuki

AU - Zhang, Pingkuan

AU - Ohe, Yuichiro

PY - 2023/5

Y1 - 2023/5

N2 - In the original publication, under section: Secondary end points, the sentence starting with: “KM estimated...” should read as: KM estimated median DoR was not reached (95% CI 13.9–not reached) in patients who had confirmed responses. The original publication has been corrected.

AB - In the original publication, under section: Secondary end points, the sentence starting with: “KM estimated...” should read as: KM estimated median DoR was not reached (95% CI 13.9–not reached) in patients who had confirmed responses. The original publication has been corrected.

UR - https://www.scopus.com/pages/publications/85146383213

UR - https://www.scopus.com/pages/publications/85146383213#tab=citedBy

U2 - 10.1007/s10147-022-02286-7

DO - 10.1007/s10147-022-02286-7

M3 - Comment/debate

C2 - 36648711

AN - SCOPUS:85146383213

SN - 1341-9625

VL - 28

SP - 724

EP - 725

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

IS - 5

ER -

Sugawara S, Kondo M, Yokoyama T, Kumagai T, Nishio M, Goto K et al. Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7). International Journal of Clinical Oncology. 2023 May;28(5):724-725. doi: 10.1007/s10147-022-02286-7

Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7)

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this